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Belatacept is an intravenously infused selective T cell costimulation blocker approved for preventing organ rejection in renal transplant recipients aged ≥18 years. This phase I trial examined the pharmacokinetics and pharmacodynamics (percentage CD86 receptor occupancy [%CD86RO]) of a single dose of belatacept (7.5 mg/kg) administered to kidney transplant recipients aged 12-17 years receiving a stable calcineurin inhibitor-based immunosuppressive regimen. Nine adolescents (mean age 15.1 years) who were seropositive for Epstein-Barr virus were enrolled; all completed the 6-month study. has been identified as a major contributor to graft loss among adolescents. 5, 6 In addition, chronic use of calcineurin inhibitors (CNIs) is associated with chronic allograft injury, including tubulointerstitial fibrosis and chronic allograft dysfunction, [7] [8] [9] [10] [11] [12] and cardiovascular and metabolic adverse events (AEs). 13 Belatacept is an intravenously infused soluble fusion protein that selectively blocks CD86-CD28 costimulation between antigen-presenting cells and T cells ( Figure S1 ). 14 and urine albumin-to-creatinine ratio <56.5 mg/mmol (<0.5 mg albumin/mg creatinine). Individuals with a history of any treated or biopsy-proven acute rejection in the 3 months before enrollment were excluded, as were individuals with any active infection.
The study conformed to Good Clinical Practice guidelines and Declaration of Helsinki principles. The protocol was approved by the institutional review board/ethics committee at the participating centers.
| Dose selection
Because belatacept had not been previously studied in adolescents, initial dose selection for this age group was based on simulations that extrapolated data from an adult population pharmacokinetic model 20 to adolescents. 21 The dose selected for use in adolescents was that necessary to achieve steady-state trough (C min ) concentrations comparable to those observed in stable adult renal transplant recipients participating in a phase II study. 22, 23 Based on the assumption that belatacept exposure at C min is highly correlated with receptor occupancy, which then drives pharmacologic activity, 20 and because it was expected that belatacept clearance would increase with decreasing age (due to generally higher metabolic rates in children), we reasoned that a higher belatacept dose was likely needed for adolescents to achieve C min similar to that observed in adults.
Thus, belatacept 7.5 mg/kg was selected as the dose to be administered to adolescents.
| Endpoints
The 
| Pharmacokinetics

| Pharmacodynamics
As previously described, 20 
| Statistical analysis
Data from nine adolescents would provide 97% confidence that the point estimate of the geometric mean would be within 20% of the true value for C max and within 20% of the true value for AUC 0-INF , assuming that C max and AUC 0-INF values were log-normally distributed with coefficients of variation of 27% and 28%, respectively.
| RE SULTS
| Patients
Nine adolescent kidney transplant recipients received a single intravenous infusion of belatacept 7.5 mg/kg, and all continued in the study to day 57 and completed the follow-up visit at month 6.
Baseline demographics and disease characteristics are summarized in 
| Pharmacokinetics
Pharmacokinetic data were available for all 9 study participants and are summarized in Table 2 Table 2 ). 
| Pharmacodynamics
Pharmacodynamic data were available for 7 study participants on day 1 (0.5 hours) and day 29, and for 5 study participants on day 57. Mean CD86RO was highest at hour 0.5 of day 1, with mean (SD) CD86RO of 94.7% (4.0) at hour 0.5 of day 1, 78.0% (11.0) at day 29, and 51.5% (43.3) at day 57. 
TA B L E 2
Pharmacokinetic parameters derived from adolescent kidney recipients administered a single dose of belatacept 7.5 mg/kg, healthy adult volunteers administered a single dose of belatacept 10 mg/kg, and adult kidney transplant recipients administered multiple doses
| Relationship between pharmacokinetics and pharmacodynamics
The highest CD86RO was observed at high belatacept concentrations and decreased as belatacept concentrations declined (Figure 1 ).
| Safety
During the protocol-specified, 57-day postdose safety monitoring period, 3 patients reported 7 AEs. Only headache occurred in more than one patient (n = 2). One patient experienced 3 AEs that were were considered by the investigator to be unrelated to belatacept.
| D ISCUSS I ON
The pharmacokinetic data derived from this phase I study of adolescent renal transplant recipients demonstrate relatively low variability of exposure to intravenously infused belatacept Saturation of the CD86 receptor has been shown to correlate with inhibition of the alloimmune response 14 and presumably a reduced risk of acute rejection episodes. High levels of CD86RO were observed in this study (94.7% on day 1). In adults, 94% occupancy of CD86 was observed on day 5. 14,20 Thus, the extent of CD86RO measured in adolescent kidney transplant recipients was comparable to that observed in adult renal transplant recipients. We observed a pharmacologic relationship between pharmacokinetics (drug concentration) and pharmacodynamics (%CD86RO), such that saturation of the CD86 receptor increased with increasing concentrations of belatacept. This relationship was also observed in adults and was best described using an E max model. 20 No new belatacept-related safety events were reported in any patient during the protocol-specified 6-month follow-up period. The data from this phase I study will be used to inform belatacept dose selection in future studies of adolescent kidney transplant recipients. 
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